RxSight/RXST

$56.10

2.57%
-
1D1W1MYTD1YMAX

About RxSight

RxSight, Inc. is a commercial-stage medical technology company. The Company is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.

Ticker

RXST

Sector

Healthcare

Trading on

NASDAQ

Industry

Misc. Capital Goods

CEO

Ron Kurtz

Employees

292

Headquarters

Aliso viejo, United States

RxSight Metrics

BasicAdvanced
$1.96B
Market cap
-
P/E ratio
-$1.68
EPS
-
Beta
-
Dividend rate

What the Analysts think about RxSight

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 8 analysts.
15.78% downside
High $54.00
Low $36.00
$56.10
Current price
$47.25
Average price target

RxSight Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-56.1% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$22.1M
6.25%
Net income
$-12.4M
-10.14%
Profit margin
-56.1%
-15.44%

RxSight Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.23%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.56
-$0.42
-$0.40
-$0.35
-
Expected
-$0.75
-$0.53
-$0.47
-$0.43
-$0.36
Surprise
-25.08%
-20.83%
-14.89%
-19.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell RxSight stock

Buy or sell RxSight stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing